First line chemotherapy of metastatic breast cancer

P. Pronzato; M. Rondini

doi:10.1093/annonc/mdj974

First line chemotherapy of metastatic breast cancer

P. Pronzato, M. Rondini

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.

Original language	English
Journal	Annals of Oncology
Volume	17
Issue number	SUPPL. 5
DOIs	https://doi.org/10.1093/annonc/mdj974
Publication status	Published - May 2006

Keywords

Chemotherapy
Metastatic breast cancer
Trastuzumab

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1093/annonc/mdj974

Fingerprint Dive into the research topics of 'First line chemotherapy of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this

@article{ed6760899dcd4309b51a263974e77ec7,

title = "First line chemotherapy of metastatic breast cancer",

abstract = "In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.",

keywords = "Chemotherapy, Metastatic breast cancer, Trastuzumab",

author = "P. Pronzato and M. Rondini",

year = "2006",

month = may,

doi = "10.1093/annonc/mdj974",

language = "English",

volume = "17",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "SUPPL. 5",

}

TY - JOUR

T1 - First line chemotherapy of metastatic breast cancer

AU - Pronzato, P.

AU - Rondini, M.

PY - 2006/5

Y1 - 2006/5

N2 - In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.

AB - In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.

KW - Chemotherapy

KW - Metastatic breast cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=33745594833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745594833&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj974

DO - 10.1093/annonc/mdj974

M3 - Article

C2 - 16807448

AN - SCOPUS:33745594833

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -